M. L. Lub-de Hooge

发表

Integrating molecular nuclear imaging in clinical research to improve anticancer therapy

R. Dierckx, S. Oosting, E. Vries, 2018, Nature Reviews Clinical Oncology.

Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer

P. L. Jager, E. Vries, M. L. Lub-de Hooge, 2010, Clinical pharmacology and therapeutics.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Ronald Boellaard, I. C. Kok, Adrienne H Brouwers, 2018, Nature Medicine.

Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study.

S. Rosati, J. Pruim, Xiaoyuan Chen, 2013, Nuclear medicine and biology.

Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.

Vasilis Ntziachristos, Maximilian Koch, Sabrina Oliveira, 2016, Cancer research.

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Vasilis Ntziachristos, Sabrina Oliveira, Bert van der Vegt, 2016, Clinical Cancer Research.

Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use.

E. D. de Vries, J. Kosterink, W. Nagengast, 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Placental Growth Factor (PlGF)–Specific Uptake in Tumor Microenvironment of 89Zr-Labeled PlGF Antibody RO5323441

E. D. de Vries, E. de Vries, F. Herting, 2013, The Journal of Nuclear Medicine.

Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging

Johan R de Jong, Marjolijn N Lub-de Hooge, Joost Bart, 2009, Journal of Nuclear Medicine.

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.

E. D. de Vries, J. Kosterink, C. Schröder, 2014, European journal of cancer.

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

C. Swanton, E. D. de Vries, U. Banerji, 2014, Clinical Cancer Research.

Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

E. D. de Vries, S. Vedelaar, H. Timmer-Bosscha, 2012, Molecular pharmaceutics.

Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets.

E. D. de Vries, G. Hospers, C. Schröder, 2010, Methods in molecular biology.

Molecular imaging of breast cancer.

E. D. de Vries, G. Hospers, E. Wall, 2009, Breast.

Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery

Vasilis Ntziachristos, Sabrina Oliveira, V. Ntziachristos, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models

M. Reiss, E. D. de Vries, R. Gregory, 2011, The Journal of Nuclear Medicine.

Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice

K. D. de Visser, M. L. Lub-de Hooge, C. Schröder, 2021, Frontiers in Oncology.

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

O. Hoekstra, E. D. de Vries, H. Verheul, 2015, Clinical Cancer Research.

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab

E. D. de Vries, S. de Jong, M. L. Lub-de Hooge, 2016, Oncotarget.

Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers—The first step towards an imaging warehouse

R. Boellaard, E. D. de Vries, S. Oosting, 2018, Theranostics.

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

S. Sleijfer, E. D. de Vries, B. van der Vegt, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

E. D. de Vries, G. Meneses‐Lorente, C. Adessi, 2017, Clinical Cancer Research.

Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors

E. D. de Vries, W. Sluiter, T. Links, 2014, The Journal of Nuclear Medicine.

89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel–Lindau Disease

E. D. de Vries, W. Sluiter, T. Links, 2016, The Journal of Nuclear Medicine.

89Zr-Onartuzumab PET imaging of c-MET receptor dynamics

E. D. de Vries, M. L. Lub-de Hooge, A. T. V. Terwisscha van Scheltinga, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

Molecular imaging: what can be used today

A. van Waarde, E. de Vries, M. L. Lub-de Hooge, 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.

B. Hazenberg, E. Vellenga, P. Hawkins, 2006, The American journal of medicine.

Preclinical characterisation of 111In‐DTPA‐trastuzumab

J. Bart, J. Kosterink, L. Tran, 2004, British journal of pharmacology.

Chemical Modification of Interleukin-10 with Mannose 6-Phosphate Groups Yields a Liver-Selective Cytokine

H. Rachmawati, M. L. Lub-de Hooge, L. Beljaars, 2007, Drug Metabolism and Disposition.

Development of a radioiodinated apoptosis–inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies

E. D. de Vries, S. de Jong, J. Kosterink, 2012, British journal of pharmacology.

The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease—A Systematic Literature Review

M. Visschedijk, N. D. de Boer, D. Touw, 2022, Pharmaceutics.

Modelling Tools to Characterize Acetaminophen Pharmacokinetics in the Pregnant Population

L. Hanff, K. Allegaert, M. L. Lub-de Hooge, 2021, Pharmaceutics.

Molecular imaging to support cancer immunotherapy

E. D. de Vries, S. Oosting, M. L. Lub-de Hooge, 2022, Journal for ImmunoTherapy of Cancer.

Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load.

E. D. de Vries, M. L. Lub-de Hooge, A. Brouwers, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Imaging in Cancer Drug Development

I. C. Kok, E. D. de Vries, M. L. Lub-de Hooge, 2018, The Journal of Nuclear Medicine.

PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys

L. Gantert, E. Hostetler, E. D. de Vries, 2020, Molecular Imaging and Biology.

Intravenous administration of recombinant human IL-10 suppresses the development of anti-thy 1-induced glomerulosclerosis in rats.

H. Bakker, H. Rachmawati, M. L. Lub-de Hooge, 2011, PDA journal of pharmaceutical science and technology.

89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma

E. D. de Vries, J. Gietema, S. Oosting, 2017, The Journal of Nuclear Medicine.

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

I. C. Kok, E. D. de Vries, R. Fehrmann, 2019, Clinical Cancer Research.

Clinical Validation of the Analysis of Fluconazole in Oral Fluid in Hospitalized Children

J. Kosterink, J. Alffenaar, M. L. Lub-de Hooge, 2014, Antimicrobial Agents and Chemotherapy.

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations.

I. C. Kok, R. Boellaard, E. de Vries, 2022, Molecular imaging and biology.

Mesothelin/CD3 Half-Life–Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues

E. D. de Vries, M. Friedrich, B. van der Vegt, 2021, The Journal of Nuclear Medicine.

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate

E. D. de Vries, M. L. Lub-de Hooge, C. Schröder, 2020, Journal for ImmunoTherapy of Cancer.

TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET

E. D. de Vries, W. D. den Dunnen, J. Gietema, 2015, The Journal of Nuclear Medicine.

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

E. D. de Vries, E. de Vries, J. Kosterink, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

E. D. de Vries, T. Suter, J. Gietema, 2007, European journal of cancer.

Biodistribution Studies of Epithelial Cell Adhesion Molecule (EpCAM)-Directed Monoclonal Antibodies in the EpCAM-Transgenic Mouse Tumor Model1

J. Kosterink, M. Harmsen, E. van Garderen, 2007, The Journal of Immunology.

The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm

E. D. de Vries, M. Friedrich, M. L. Lub-de Hooge, 2020, The Journal of Nuclear Medicine.

Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors

E. D. de Vries, M. Friedrich, H. Cheung, 2018, Clinical Cancer Research.

Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Patrick K. Kimes, T. Kwee, R. Fehrmann, 2022, Nature Medicine.

Development and Evaluation of Interleukin-2–Derived Radiotracers for PET Imaging of T Cells in Mice

G. Bormans, G. Hospers, E. de Vries, 2020, The Journal of Nuclear Medicine.

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

E. D. de Vries, A. Jorritsma-Smit, M. L. Lub-de Hooge, 2020, Journal for ImmunoTherapy of Cancer.

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

E. D. de Vries, R. Fehrmann, S. Oosting, 2020, Theranostics.

Diagnostic Performance and Prognostic Value of Extravascular Retention of 123I-Labeled Serum Amyloid P Component in Systemic Amyloidosis

B. Hazenberg, E. Vellenga, P. L. Jager, 2007, Journal of Nuclear Medicine.

Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.

E. D. de Vries, B. Overmoyer, B. van der Vegt, 2015, Pharmacology & therapeutics.

Molecular imaging to enlighten cancer immunotherapies and underlying involved processes.

E. D. de Vries, A. Glaudemans, M. L. Lub-de Hooge, 2018, Cancer treatment reviews.

Antibody positron emission tomography imaging in anticancer drug development.

E. D. de Vries, J. Gietema, Simon-Peter Williams, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds

E. D. de Vries, J. Kosterink, M. L. Lub-de Hooge, 2018, Medicinal research reviews.

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

H. Hollema, E. D. de Vries, P. Price, 2011, Cancer research.

In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft

H. Hollema, G. V. van Dongen, E. D. de Vries, 2007, Journal of Nuclear Medicine.

First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

I. C. Kok, O. Vasiljeva, E. D. de Vries, 2021, Clinical Cancer Research.

Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging.

M. Reiss, E. D. de Vries, H. Timmer-Bosscha, 2012, Pharmacology & therapeutics.

Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer.

E. D. de Vries, M. L. Lub-de Hooge, A. Brouwers, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2009, Clinical Cancer Research.

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.

E. D. de Vries, M. L. Lub-de Hooge, D. D. de Groot, 2019, Pharmacology & therapeutics.

Theranostics Using Antibodies and Antibody-Related Therapeutics

I. C. Kok, Mathilde Jalving, Marjolijn N. Lub-de Hooge, 2017, The Journal of Nuclear Medicine.

Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model

A. V. D. Van Der Zee, E. D. de Vries, S. de Jong, 2012, Clinical Cancer Research.

Immuno-PET: a navigator in monoclonal antibody development and applications.

G. V. van Dongen, E. D. de Vries, M. L. Lub-de Hooge, 2007, The oncologist.

Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy.

E. D. de Vries, T. Kwee, A. van den Berg, 2020, The Lancet. Haematology.

Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Marjolijn N Lub-de Hooge, Elisabeth G E de Vries, Erik T Garbacik, 2013, Cancer research.

89Zr-Bevacizumab PET Imaging in Primary Breast Cancer

R. Pleijhuis, J. Bart, E. D. de Vries, 2012, The Journal of Nuclear Medicine.

In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin 89Zr-PRS-110 PET Tracer

E. D. de Vries, J. Kosterink, L. Audoly, 2014, The Journal of Nuclear Medicine.

Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM

E. D. de Vries, J. Kosterink, M. Friedrich, 2016, The Journal of Nuclear Medicine.

89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice

E. de Vries, L. Broer, A. Cuthbertson, 2022, The Journal of Nuclear Medicine.

Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192

S. de Jong, G. Hospers, E. de Vries, 2020, The Journal of Nuclear Medicine.

Relative blood volume changes underestimate total blood volume changes during hemodialysis.

Marjolijn N Lub-de Hooge, Jan Pruim, J. Pruim, 2007, Clinical journal of the American Society of Nephrology : CJASN.

Roadmap for the Development and Clinical Translation of Optical Tracers Cetuximab-800CW and Trastuzumab-800CW

Gooitzen M van Dam, Matthijs D Linssen, Eva J Ter Weele, 2019, The Journal of Nuclear Medicine.

Pharmacokinetic Boosting of Kinase Inhibitors

J. Kosterink, D. Touw, M. L. Lub-de Hooge, 2023, Pharmaceutics.

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation

R. Boellaard, E. D. de Vries, G. Hospers, 2016, The Journal of Nuclear Medicine.

89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922

H. Hollema, G. V. van Dongen, E. D. de Vries, 2010, Journal of Nuclear Medicine.

89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment

H. Hollema, E. D. de Vries, S. Scherer, 2015, The Journal of Nuclear Medicine.

Human Epidermal Growth Factor Receptor 3–Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging

E. de Vries, J. Kosterink, C. Knuehl, 2017, The Journal of Nuclear Medicine.

Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy.

E. D. de Vries, J. Kosterink, M. L. Lub-de Hooge, 2008, Current pharmaceutical design.

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue

O. Vasiljeva, E. D. de Vries, L. Broer, 2020, Clinical Cancer Research.

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

E. D. de Vries, S. de Jong, M. L. Lub-de Hooge, 2017, mAbs.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116

E. D. de Vries, J. Kosterink, B. Bossenmaier, 2014, mAbs.

Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans

Annelies Jorritsma-Smit, Elly L. van der Veen, Inês F. Antunes, 2019, EJNMMI Radiopharmacy and Chemistry.

Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo.

Ruchi Bansal, J. Prakash, M. L. Lub-de Hooge, 2009, Neoplasia.

Theranostics Using Antibodies and Antibody-Related Therapeutics

I. C. Kok, E. D. de Vries, R. Fehrmann, 2017, The Journal of Nuclear Medicine.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

I. C. Kok, R. Boellaard, H. Groen, 2018, Nature Medicine.

Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab

R. Boellaard, A. Lammertsma, A. Willemsen, 2023, The Journal of Nuclear Medicine.

Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors

S. Oosting, M. L. Lub-de Hooge, A. Brouwers, 2014, The Journal of Nuclear Medicine.